Second Department of Medicine, University of Toyama, 2630 Sugitani Toyama, Toyama 930-0194, Japan.
Medicina (Kaunas). 2020 Mar 4;56(3):110. doi: 10.3390/medicina56030110.
Optimal patient selection for cardiac resynchronization therapy is crucial. There are several concerns that allow to better clarify the association between the ischemic etiology of heart failure and the response to cardiac resynchronization therapy. The type of ischemic coronary disease has an impact on the responses to cardiac resynchronization therapy. The prognostic impact of cardiac resynchronization therapy on cardiac death including heart transplantation and durable ventricular assist device implantation is another concern.
优化心脏再同步治疗的患者选择至关重要。有几个关注点可以更好地阐明心力衰竭的缺血性病因与心脏再同步治疗反应之间的关系。缺血性冠状动脉疾病的类型对心脏再同步治疗的反应有影响。心脏再同步治疗对心脏性死亡（包括心脏移植和持久心室辅助装置植入）的预后影响是另一个关注点。
